• 1
    Leo ME, Bilhartz DL, Bergstralh EJ, Oesterling JE. Prostate specific antigen in hormonally treated stage D2 prostate cancer. Is it always an accurate indicator of disease status? J Urol 1991; 145: 802 6
  • 2
    Lorente JA, Morote J, Raventos C, Encabo G, Valenzuela H. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. J Urol 1996; 155: 134851
  • 3
    Horti J, Dixon SC, Logothetis CJ, Guo Y, Reed E, Figg WD. Increased transcriptional activity of PSA in the presence of TNP-470, an angiogenesis inhibitor. Br J Cancer 1999; 79: 1588 93
  • 4
    Bauer KS, Figg WD, Hamilton JM et al. A pharmacokinetically guided phase II study of carboxyamido-triazole (CAI) in androgen independent prostate cancer. Clin Cancer Res 1999; 5: 23249
  • 5
    Schaffer DL, Pendergrass HP. Comparison of enzyme, clinical, radiographic, and radionuclide methods of detecting bone metastases from carcinoma of the prostate. Radiology 1976; 121: 4314
  • 6
    Amico S, Liehn JC, Desoize B, Larbre H, Deltour G, Valeyre J. Comparison of phosphate isoenzymes PAP and PSA with bone scan in patients with prostate carcinoma. Clin Nucl Med 1991; 16: 6438
  • 7
    Chybowski FM, Keller JL, Bergstralh EJ, Oesterling JE. Predicting radionuclide bone scan findings in patients with newly diagnosed untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol 1991; 145: 3138
  • 8
    Soloway MS, Hardeman SW, Hickey D et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial scan. Cancer 1988; 61: 195202
  • 9
    Noguchi M, Kikuchi H, Noda S. Percentage of the positive area of bone metastasis is an independent predictor of the disease death in advanced prostate cancer. Br J Cancer 2003; 88: 195201
  • 10
    Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 20516
  • 11
    Bubley GJ, Carducci M, Dahut W et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendation from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17: 34617
  • 12
    Dann J, Castronovo FP Jr, McKusick KA, Griffin PP, Strauss HW, Pout GR Jr. Total bone uptake in management of metastatic carcinoma of the prostate. J Urol 1987; 137: 4448
  • 13
    Sabbatini P, Yeung H, Imbriaco M et al. The correlation of serial bone scintigraphy and PSA determinations in patients (Pts) with androgen independent prostate cancer (AIPC). Proc Am Soc Clin Oncol 1996; 15: 254 (A653)
  • 14
    Imbriaco M, Larson SM, Yeung HW et al. A new parameter for measuring metastatic bone involvement by prostate cancer: The bone scan index. Clin Cancer Res 1998; 4: 176572
  • 15
    Sabbatini P, Larson SM, Kremer A et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 1999; 17: 94857
  • 16
    Erdi YE, Humm JL, Imbrico M, Yeung H, Larson M. Quantitative bone metastases analysis based on image segmentation. J Nucl Med 1997; 38: 14016
  • 17
    Noguchi M, Stamey TA, McNeal JE, Yemoto CE. Assessment of morphometric measurements of prostate cancer volume. Cancer 2000; 89: 105664
  • 18
    Scher HI, Mazumdar K, Kelly WK. Clinical trials in relapsed prostate cancer: defining the target. J Nat Cancer Inst 1996; 88: 162330
  • 19
    Kelly WK, Scher HI, Mazumda K, et al. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 1993; 11: 60712